SWSteven L. Werlin

Steven L. Werlin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Steven L. Werlin has a total of 51 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Trainee Involvement on Pediatric ERCP Procedures

    by Rekha Gupta, Racha Khalaf, John Morrison, Ernest Amankwah, Wenly Ruan, Douglas S Fishman, Bradley A Barth, Quin Y Liu, Matthew Giefer, Kyung Mo Kim, et al.

    This study examines the role of trainee involvement with pediatric endoscopic retrograde cholangiopancreatography (ERCP) and whether it affects the procedure’s success, post‐procedural adverse outcomes, and duration. A secondary analysis of the Pediatric ERCP Database Initiative, an international database, was performed. Consecutive ERCPs on children 0.05). Fewer cases involving trainees were in the top quartile (>58 minutes) of procedural time (19% vs 26%; P = 0.02). Overall, our findings indicate trainee involvement in pediatric ERCP is safe.


  • Acute Pancreatitis

    by Jonathan Wong, Praveen S. Goday, Steven L. Werlin

  • Outcomes after fecal diversion for colonic and perianal Crohn disease in children

    by Rajmohan Dharmaraj, Melodee Nugent, Pippa Simpson, Marjorie Arca, Bhaskar Gurram, Steven Werlin


  • Acute Pancreatitis

    by Alisha Mavis, Praveen S. Goday, Steven L. Werlin


  • Pancreatic Insufficiency

    by Praveen S. Goday, Steven L. Werlin

  • Open Access

    Calprotectin in Cystic Fibrosis

    by Nisreen Rumman, Mutaz Sultan, Khalil El-Chammas, Vi Goh, Nita Salzman, Diana Quintero, Steven Werlin

    There is increasing evidence that intestinal inflammation plays a major role in gastrointestinal symptoms in cystic fibrosis (CF). Fecal calprotectin is a marker that is elevated in several gastrointestinal inflammatory diseases, but little is known about its value in CF. We aimed to look for associations of elevated fecal calprotectin among CF patients and whether its level correlates with the clinical manifestations of CF.


  • Obesity in Pediatric Celiac Disease

    by Narayanan Venkatasubramani, Grzegorz Telega, Steven L Werlin

    Background and Aim: Celiac disease (CD) is a T cell–mediated chronic autoimmune enteropathy occurring in genetically susceptible individuals, and manifested by a permanent intolerance to gluten‐containing products. CD commonly presents in children as failure to thrive and malabsorption or after screening high‐risk groups such as people with diabetes. Almost half of adult patients with CD have a body mass index (BMI) >25 at diagnosis. Classic symptoms like diarrhea are less common in obese patients. Few children have been reported with CD and obesity. Because many children with newly diagnosed CD are identified by screening high‐risk groups, obesity is more common than previously suspected. The aim of the study was to estimate the prevalence of obesity at diagnosis in children with CD and to describe the clinical characteristics of this group.Patients and Methods: This is a retrospective study of 143 patients with CD diagnosed between 1986 and 2003 at Children's Hospital of Wisconsin. Data collected included patient's age, sex, ethnicity, presenting signs and symptoms, BMI, celiac antibody titers, small‐intestinal biopsy results, and follow‐up weight 1 year after initiating a gluten‐free diet (GFD).Results: Seven of the 143 (5%) patients had BMI >95th percentile. The most common presenting symptoms among obese patients were abdominal pain, diabetes, and diarrhea. Symptoms improved in all of the patients on a GFD. BMI decreased in 4 (50%), increased in 2 (25%), and was not available in 1 patient at 1 year after starting on GFD.Conclusions: Obesity is more common in children with CD than previously recognized. In the appropriate clinical setting, CD must be considered even in obese children.


  • The use of magnetic resonance cholangiopancreatography in children

    by Neelesh A. Tipnis, Steven L. Werlin

    Magnetic resonance cholangiopancreatography (MRCP) is a noninvasive method to evaluate a wide variety of pancreatobiliary disorders. These disorders include choledochal cyst, cholelithiasis, choledocholithiasis, biliary atresia, Caroli’s disease, primary sclerosing cholangitis, disorders of the pancreatobiliary junction, pancreas divisum, and pancreatic duct abnormalities related to chronic pancreatitis. The use of MRCP in children is increasing as experience with MRCP grows, and its technological accuracy rivals that of endoscopic evaluation. We review the current state of MRCP use in children.


  • The Spectrum of Valproic Acid–Associated Pancreatitis

    by Steven L. Werlin, Daryl L. Fish

    OBJECTIVE. Our goal was to characterize valproic acid–associated pancreatitis in children.PATIENTS AND METHODS. The charts of all patients with pancreatitis (diagnosed by using strict criteria) associated with valproic acid during a 10-year period were reviewed. Clinical and laboratory results were abstracted.RESULTS. Twenty-two patients with valproic acid–associated pancreatitis were seen during the study period. Symptoms were similar to those of patients with pancreatitis from other etiologies and included abdominal pain/tenderness (83%), vomiting/retching (74%), abdominal distention (30%), and fever/chills (26%). Valproic acid levels were in the therapeutic range in all but 1 patient. The mean duration of therapy before the onset of pancreatitis was 32 months. The serum lipase level was >3 times the reference value in all patients, but the serum amylase level was not significantly elevated in 31% of the patients tested. Imaging studies altered clinical management in only 1 patient. The length of stay was generally brief (mean: 8 days). Two patients died. Of the 5 patients who were rechallenged, 4 had relapses.CONCLUSIONS. Valproic acid–associated pancreatitis does not depend on valproic acid serum level and may occur any time after the onset of therapy. The serum lipase level is more sensitive than the serum amylase level and should be obtained when pancreatitis is suspected. Early imaging studies did not change clinical management. Rechallenge with valproic acid is dangerous and should be avoided.


  • Superior Mesenteric Artery Syndrome in Children

    by Vincent Biank, Steven Werlin

    Objectives: Superior mesenteric artery syndrome (SMAS), Wilkie syndrome or cast syndrome is a rare condition that usually presents with symptoms of mid to upper gastrointestinal obstruction due to the compression of the duodenum between the abdominal aorta, posteriorly, and the superior mesenteric artery, anteriorly. The aim of this study was to analyze the clinical characteristics, means of diagnosis and management of SMAS in a pediatric population.Methods: Retrospective chart review of all patients at the Children's Hospital of Wisconsin with SMAS from 1985 to 2005.Results: Twenty‐two cases of SMAS where diagnosed at Children's Hospital of Wisconsin between 1985 and 2005 [14, (64%) female]. Symptoms developed 1 to 393 days (median 5 days) before diagnosis. Presenting symptoms included abdominal pain (59%), vomiting (50%), nausea (40%), early satiety (32%) and anorexia (18%). Diagnosis was made by upper‐gastrointestinal radiography in 18 (82%), by computed tomography in 2 (9%) and at laparotomy in 2 (9%). One patient was treated surgically after medical management failed. Mean length of treatment was 65 days (range 13‐169), with a mean length of hospitalization of 21 days (range 0‐68 days).Conclusion: SMAS usually presents more acutely than chronically with symptoms of small bowel obstruction. Weight loss is not necessary for SMAS development. Prior neurological injury may be a risk factor for development of SMAS. Upper gastrointestinal radiography remains the primary means of diagnosis. SMAS is typically successfully managed medically. Surgical intervention should be reserved for patients' refractory to medical therapy. The expected outcome of SMAS is excellent.